Molecular screening with liquid biopsy for anti-EGFR retreatment in metastatic colorectal cancer: preliminary data from the randomized phase 2 PARERE trial.

Background

Retreatment with anti-EGFR monoclonal antibodies is a promising strategy in patients with

Methods

Patients with

Results

A total of 218 patients underwent LB, and ctDNA sequencing was successful in 201 of them (92%).

Conclusions

This is the largest prospective cohort of mCRC patients screened with LB for anti-EGFR retreatment in a randomized study. ctDNA genotyping reveals that at least one out of three patients candidate for retreatment should be excluded from this therapy, and other potential drivers of anti-EGFR resistance are found in approximately one out of three patients with

Informations de copyright

Copyright © 2024 Germani, Vetere, Giordano, Ciracì, Capone, Tamborini, Conca, Busico, Pietrantonio, Piva, Boccaccino, Simionato, Bortolot, Manca, Lonardi, Conca, Borelli, Carullo, Del Re, Fontanini, Rossini and Cremolini.

Déclaration de conflit d'intérêts

SL: consulting or an advisory role—Amgen, Merck Serono, Lilly, AstraZeneca, Incyte, Daiichi-Sankyo, BMS, Servier, and MSD; research funding—Amgen, Merck Serono, Bayer, Roche, Lilly, AstraZeneca, and BMS; speakers’ fees from Roche, Lilly, BMS, Servier, Merck Serono, Pierre-Fabre, GlaxoSmithKline, and Amgen. FP: honoraria—Merck-Serono, Amgen, Bayer, Servier, Takeda, Pierre-Fabre, MSD, BMS, and Astellas; research grants for non-profit studies—AstraZeneca, BMS, Agenus, Amgen. CC: honoraria—Amgen, Bayer, Merck, Roche, and Servier; consulting or advisory role—Amgen, Bayer, MSD, and Roche; speakers’ bureau—Servier; research funding—Bayer, Merck, and Servier; travel, accommodations, and expenses—Roche and Servier. DR: honoraria—Takeda Pharmaceuticals. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.